Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05080842 · ClinicalTrials.gov registry record · Phase 1
A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer
A Phase 1 study, sponsored by Accutar Biotechnology.
- Terminated
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT05080842 is a Phase 1 study that was terminated before completion, run by Accutar Biotechnology. The registered enrollment target is 21 participants.
The verdict
NCT05080842, a Phase 1 study, was terminated before completion, sponsored by Accutar Biotechnology.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
This clinical trial is evaluating a drug called AC682 in participants with estrogen receptor positive/human epidermal growth factor 2 negative (ER+/HER2-) locally advanced or metastatic breast cancer. The main goals of this study are to: * Identify the recommended dose of AC682 that can be given safely to participants * To evaluate the side effects of AC682 * To evaluate pharmacokinetics of AC682 * To evaluate the effectiveness of AC682
Interventions
- DRUG AC682
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2021-11-12 |
| Est. Completion | 2024-04-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05080842
The ClinicalTrials.gov registry entry for NCT05080842 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Accutar Biotechnology, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AC682 is the first listed.
NCT05080842 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05080842 about?
NCT05080842 is a clinical study titled "A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer". This clinical trial is evaluating a drug called AC682 in participants with estrogen receptor positive/human epidermal growth factor 2 negative (ER+/HER2-) locally advanced or metastatic breast cancer. The main goals of this study are to: * Identify the recommended dose of AC682 that can be given sa...
What is the current status of trial NCT05080842?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2021-11-12. Estimated completion is 2024-04-04.
What interventions are being tested in trial NCT05080842?
The interventions under investigation include: AC682 (DRUG).
Who is sponsoring clinical trial NCT05080842?
This trial is sponsored by Accutar Biotechnology, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.